ClinicalTrials.gg
Not yet recruitingNCT07858084SDM-ConsentUpdated Nov 16, 2026

Shared Decision-Making During Anesthesia Consent for Elective Cesarean Delivery

An observational study in Shared Decision Making, Cesarean Section and Anesthesia, Obstetrical, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of British Columbia · Observational

How we know

Updated Nov 16, 2026Start date movedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
105
Ages
19 Years and older
Sex
Female
01

Study summary

Shared decision-making (SDM) is the accepted ethical and legal standard for informed consent, but it is not known how it operates in anesthesia consent for cesarean delivery. Neuraxial anesthesia is recommended for most cesarean deliveries, and many anesthesiologists therefore present it as the only primary option, with general anesthesia (GA) available only as a rescue. Others present GA as a genuine alternative the patient can choose. This study will observe the existing variation in practice and will not change care. A trained observer will attend the pre-operative anesthesia consent encounter for women having an elective cesarean delivery at BC Women's Hospital and record which options were presented, using the observer-rated OPTION-5 instrument. Written research consent and a questionnaire follow on postpartum day 1 or 2, and include the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The primary aim is to compare patient-perceived SDM (SDM-Q-9) between consultations in which GA was offered as a genuine primary option and those in which it was not. This study hypothesizes that the SDM-Q-9 score will be higher when GA was offered as a primary option. Secondary aims are to describe observed SDM, decisional conflict, provider-level variation, and women's preference to be offered a choice in a future cesarean. The findings will inform a planned interventional trial of a standardized consent model.

Read the detailed description

Background. SDM, in which the clinician contributes evidence and the patient contributes values and preferences, is the ethical and increasingly the legal standard of consent (Hopp v Lepp; Reibl v Hughes; Montgomery v Lanarkshire). Major guidelines recommend neuraxial anesthesia for cesarean delivery because of the higher maternal risk of GA, and the SOAP Center of Excellence benchmark is a GA rate below 5%. Choice of technique is nevertheless preference-sensitive (being awake or asleep at the birth, partner presence, fear of needles or of awareness, prior trauma), and GA is routinely delivered when clinically required. Neuraxial block fails in about 5% of cesarean deliveries and intraoperative pain occurs in roughly 11-22%, a leading cause of maternal dissatisfaction and medicolegal action. The institutional consent discloses these risks. What varies between providers is choice: some present GA as a genuine primary option alongside neuraxial anesthesia, while others present neuraxial as the sole primary technique with GA only as rescue. A departmental poll found that 6 of 21 anesthesiologists (29%) report offering GA as a primary option. It is unknown whether offering GA as a genuine primary option affects women's perception of SDM.

Design. Single-centre, prospective, cross-sectional study at BC Women's Hospital, Vancouver. It combines (a) structured direct observation of the pre-operative anesthesia consent encounter and (b) a patient questionnaire on the 1st or 2nd postpartum day. No change is made to clinical care or to the consent process; existing variation in practice is the exposure. Because the anesthesiologist is assigned by the duty rota, women are quasi-randomly exposed to consent with or without a genuine primary choice.

Recruitment. A member of the circle of care (admitting nurse) asks the patient on the day of surgery whether they are willing to be approached. Only if they agree does a trained observer introduce the study and seek verbal consent to observation. Written informed consent is obtained on postpartum day 1 or 2 by a trained research assistant who is not the observer. The clinical anesthesia consent (routine care, observed) and the research consent (written, not observed) are separate processes. Providers receive an individual information sheet with an opt-out, and no per-case feedback is given. The specific exposure of interest is withheld from providers until study end; providers are not deceived about being observed. All anesthesiologists on the obstetric call roster, including the investigators, may be observed as consenting providers. In the calibration and reliability phase, the consenting provider may also be an anesthesia resident or fellow, who receives the same information sheet and opt-out.

Measures. Exposure: observer-classified offer of GA as a genuine primary option (yes/no). GA is classified as a genuine primary option when the provider presents it as an alternative the patient may choose for this delivery, alongside neuraxial anesthesia, whether or not the patient raised it first; GA mentioned only as a rescue or backup, or not mentioned, is classified as no choice offered. Observed SDM: OPTION-5. Perceived SDM: SDM-Q-9 (primary outcome). Decisional conflict: Decisional Conflict Scale, descriptive. Future-choice preference. Covariates: age, parity, prior cesarean, prior anesthesia experience, education, gestational age, technique received, consultation duration.

Observer calibration and reliability. Before recruitment, observers are calibrated against a reference rater (the Principal Investigator) on 10-15 real pre-operative consent consultations, completed together with the habituation run-in. An observer collects study data only after reaching ICC >= 0.70 for the OPTION-5 total and kappa >= 0.70 for the exposure classifier. Patients in this phase are not enrolled: they give verbal consent to the presence of two observers, and only the observers' anonymous ratings are retained, for reliability analysis only. During recruitment, enrolled encounters are double-rated periodically (about one to two per month); the trained observer's ratings enter the analysis and the second observer's ratings are used for reliability only.

Sample size and analysis. The primary analysis is a linear mixed-effects model with a random intercept for consenting provider, adjusted for covariates, reporting the adjusted mean difference with its 95% CI and the provider-level ICC. Assuming SD 12.4, alpha 0.05, a difference of 13.5 points, and ICC 0.10, 84 analyzable patients (4 per provider across 21 providers) give 97.7% power. Allowing about 20% attrition, the recruitment target is 105. A blinded biostatistician check of ICC, exposure split and SD after the first 105 patients will verify power; any increase in sample size will be submitted to the REB as an amendment. A pre-specified sensitivity analysis repeats the primary analysis excluding encounters in which an investigator was the consenting provider. Inter-rater reliability is reported as the ICC (two-way random effects, absolute agreement, single measures) for the OPTION-5 total and as Cohen's kappa for categorical elements, each with a 95% CI. Reporting follows STROBE.

Data. Data are held in the institutional BCCHR/PHSA-hosted REDCap instance, keyed by study ID, with the re-identification key stored separately. Records are retained for 5 years after study completion and publication.

02

Conditions studied

  • Shared Decision Making
  • Cesarean Section
  • Anesthesia, Obstetrical
  • Informed Consent

Keywords

  • shared decision-making
  • anesthesia consent
  • cesarean delivery
  • general anesthesia
  • neuraxial anesthesia
  • SDM-Q-9
  • OPTION-5
  • patient-centred communication
  • obstetric anesthesia
03

In context

Lead sponsor

University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 19 or older having an elective cesarean delivery at 37 weeks or later at BC Women's Hospital, with anesthesia consent obtained on the day of surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 years or older
  • Elective (scheduled) cesarean delivery at 37 weeks' gestation or later
  • Anesthesia consent obtained on the day of surgery
  • Anesthesia consent performed in English without an interpreter
  • Capacity to consent to research participation

Exclusion criteria

Exclusion Criteria:

  • Conversion to urgent/emergency cesarean delivery before consent is completed
  • Severe maternal or neonatal complication making participation inappropriate (assessed case by case with the clinical team)
  • to neuraxial anesthesia
  • Patient declines observation pre-operatively, or declines or withdraws study consent postpartum
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
105 participants (estimated)
Patient registry
No

Groups and cohorts

  • GA offered as a primary option

    Women whose observed pre-operative anesthesia consent presented general anesthesia as a genuine primary option the patient could choose, alongside neuraxial anesthesia, whether or not the patient raised it first. Classified per consultation by the trained observer.

    Other: Observation of anesthesia consent encounter and postpartum questionnaire

  • Neuraxial only, GA as rescue

    Women whose observed pre-operative anesthesia consent presented neuraxial anesthesia as the sole primary technique, with general anesthesia available only as a rescue, or in which general anesthesia was not mentioned.

    Other: Observation of anesthesia consent encounter and postpartum questionnaire

Interventions

  • OtherObservation of anesthesia consent encounter and postpartum questionnaire

    A trained non-treating observer attends and rates the routine pre-operative anesthesia consent encounter (OPTION-5). The patient completes a questionnaire on postpartum day 1 or 2 (SDM-Q-9, Decisional Conflict Scale). No change to clinical care.

06

What researchers measure

Primary outcomes

  1. Patient-perceived shared decision-making (SDM-Q-9 score)

    Between-group difference in SDM-Q-9 total score (0-45), (higher = greater perceived involvement), between women whose consent included GA as a genuine primary option and those whose consent did not. Analysed with a linear mixed-effects model with a random intercept for consenting provider.

    Time frame: Post-operative day 1 or 2

Secondary outcomes

  1. Proportion with adequate SDM-Q-9 score

    Proportion of patients with an adequate 9-item Shared-Decision Making Score (SDM-Q-9,) score 0-45, transformed to a 0-100% scale, and using the top-box method to determine adequate (\>75%) vs inadequate (\<75%) scores, compared between exposure groups.

    Time frame: Post-operative day 1 or 2

  2. Observed shared decision-making (OPTION-5)

    Observer-rated OPTION-5 score (0-20), with higher scores meaning higher observed levels of shared-decision making between provider and patient, overall and by exposure group, with concordance with the SDM-Q-9.

    Time frame: Day of surgery, within 15 minutes of the consent encounter

  3. Provider variability in offering choice

    Proportion of consultations in which a genuine primary choice was offered; between-provider variation (ICC); whether offers were provider-initiated or prompted by patient questions; disclosure elements delivered.

    Time frame: Day of surgery, at the consent encounter

  4. Decisional conflict (Decisional Conflict Scale, 16-item)

    DCS score by exposure group, reported descriptively (mean, 95% CI, proportion above 37.5, and floor proportion).

    Time frame: Post-operative day 1 or 2

  5. Preference for future choice

    Proportion of women who would want to be offered a choice between neuraxial and general anesthesia in a future cesarean, overall and by exposure group and technique received.

    Time frame: Post-operative day 1 or 2

07

Study locations

1 site
08

References and documents

Publications

  • Charles EA, Carter H, Stanford S, Blake L, Eley V, Carvalho B, Sultan P, Kua J, O'Carroll JE. Intraoperative Pain during Cesarean Delivery under Neuraxial Anesthesia: A Systematic Review and Meta-analysis. Anesthesiology. 2025 Jul 1;143(1):156-167. doi: 10.1097/ALN.0000000000005486. Epub 2025 Apr 4. PubMed 40184602 ↗
  • Guglielminotti J, Landau R, Li G. Adverse Events and Factors Associated with Potentially Avoidable Use of General Anesthesia in Cesarean Deliveries. Anesthesiology. 2019 Jun;130(6):912-922. doi: 10.1097/ALN.0000000000002629. PubMed 30789362 ↗
  • Stacey D, Lewis KB, Smith M, Carley M, Volk R, Douglas EE, Pacheco-Brousseau L, Finderup J, Gunderson J, Barry MJ, Bennett CL, Bravo P, Steffensen K, Gogovor A, Graham ID, Kelly SE, Legare F, Sondergaard H, Thomson R, Trenaman L, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2024 Jan 29;1(1):CD001431. doi: 10.1002/14651858.CD001431.pub6. PubMed 38284415 ↗
  • SOAP 2026 Centers of Excellence: Defining Excellence in Obstetric Anesthesia Care [Internet]. Milwaukee: Society for Obstetric Anesthesia and Perinatology; 2026 Jun 12 [cited 2026 Jun 26]. Available from: https://soap.memberclicks.net/assets/COE/2026Materials/RL4%20DG%20JM%20June%2012%20SOAP%20Centers%20of%20Excellence_%20Defining%20Excellence%20in%20Obstetric%20Anesthesia%20Care%20JM_GA_6.12.26.pdf
  • Heywood R. R.I.P. SIDAWAY: PATIENT-ORIENTED DISCLOSURE-A STANDARD WORTH WAITING FOR? Montgomery v Lanarkshire Health Board[2015] UKSC 11. Med Law Rev. 2015 Summer;23(3):455-66. doi: 10.1093/medlaw/fwv024. Epub 2015 May 28. No abstract available. PubMed 26023076 ↗
  • Reibl v Hughes [1980] 2 SCR 880 (SCC).
  • Hopp v Lepp [1980] 2 SCR 192 (SCC).
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7. doi: 10.1016/S0140-6736(07)61602-X. PubMed 18064739 ↗
  • McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014 Mar;67(3):267-77. doi: 10.1016/j.jclinepi.2013.08.015. Epub 2013 Nov 22. PubMed 24275499 ↗
  • Linder SK, Swank PR, Vernon SW, Mullen PD, Morgan RO, Volk RJ. Validity of a low literacy version of the Decisional Conflict Scale. Patient Educ Couns. 2011 Dec;85(3):521-4. doi: 10.1016/j.pec.2010.12.012. Epub 2011 Feb 5. PubMed 21300518 ↗
  • O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. doi: 10.1177/0272989X9501500105. PubMed 7898294 ↗
  • Stubenrouch FE, Mus EMK, Lut JW, Hesselink EM, Ubbink DT. The current level of shared decision-making in anesthesiology: an exploratory study. BMC Anesthesiol. 2017 Jul 12;17(1):95. doi: 10.1186/s12871-017-0386-3. PubMed 28701156 ↗
  • Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010 Jul;80(1):94-9. doi: 10.1016/j.pec.2009.09.034. Epub 2009 Oct 30. PubMed 19879711 ↗
  • Barr PJ, O'Malley AJ, Tsulukidze M, Gionfriddo MR, Montori V, Elwyn G. The psychometric properties of Observer OPTION(5), an observer measure of shared decision making. Patient Educ Couns. 2015 Aug;98(8):970-6. doi: 10.1016/j.pec.2015.04.010. Epub 2015 Apr 29. PubMed 25956069 ↗
  • Elwyn G, Tsulukidze M, Edwards A, Legare F, Newcombe R. Using a 'talk' model of shared decision making to propose an observation-based measure: Observer OPTION 5 Item. Patient Educ Couns. 2013 Nov;93(2):265-71. doi: 10.1016/j.pec.2013.08.005. Epub 2013 Aug 27. PubMed 24029581 ↗
  • McCombe K, Bogod DG. Learning from the Law. A review of 21 years of litigation for pain during caesarean section. Anaesthesia. 2018 Feb;73(2):223-230. doi: 10.1111/anae.14119. Epub 2017 Nov 1. PubMed 29090735 ↗
  • Plaat F, Stanford SER, Lucas DN, Andrade J, Careless J, Russell R, Bishop D, Lo Q, Bogod D. Prevention and management of intra-operative pain during caesarean section under neuraxial anaesthesia: a technical and interpersonal approach. Anaesthesia. 2022 May;77(5):588-597. doi: 10.1111/anae.15717. Epub 2022 Mar 24. PubMed 35325933 ↗
  • Kinsella SM. A prospective audit of regional anaesthesia failure in 5080 Caesarean sections. Anaesthesia. 2008 Aug;63(8):822-32. doi: 10.1111/j.1365-2044.2008.05499.x. Epub 2008 Jun 28. PubMed 18547291 ↗
  • Ayers S, Bond R, Bertullies S, Wijma K. The aetiology of post-traumatic stress following childbirth: a meta-analysis and theoretical framework. Psychol Med. 2016 Apr;46(6):1121-34. doi: 10.1017/S0033291715002706. Epub 2016 Feb 16. PubMed 26878223 ↗
  • Vedam S, Stoll K, Taiwo TK, Rubashkin N, Cheyney M, Strauss N, McLemore M, Cadena M, Nethery E, Rushton E, Schummers L, Declercq E; GVtM-US Steering Council. The Giving Voice to Mothers study: inequity and mistreatment during pregnancy and childbirth in the United States. Reprod Health. 2019 Jun 11;16(1):77. doi: 10.1186/s12978-019-0729-2. PubMed 31182118 ↗
  • Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb;124(2):270-300. doi: 10.1097/ALN.0000000000000935. No abstract available. PubMed 26580836 ↗
  • Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, Tomson D, Dodd C, Rollnick S, Edwards A, Barry M. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012 Oct;27(10):1361-7. doi: 10.1007/s11606-012-2077-6. Epub 2012 May 23. PubMed 22618581 ↗
  • Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997 Mar;44(5):681-92. doi: 10.1016/s0277-9536(96)00221-3. PubMed 9032835 ↗

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data (IPD). De-identified data may be made available if required by a journal as a condition of publication, subject to institutional, ethical, and privacy requirements.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 16, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPatient-perceived shared decision-making (SDM-Q-9 score): how it is measured was reworded
Oct 8, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionObserved shared decision-making (OPTION-5): how it is measured was reworded
  • DescriptionProportion with adequate SDM-Q-9 score: how it is measured was reworded
Oct 8, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Nov 16, 2026
    Start date Oct 2026→Nov 2026
    + 3 other changes: verification date, description and arm descriptions
  2. Oct 8, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPatient-perceived shared decision-making (SDM-Q-9 score): how it is measured was reworded
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionObserved shared decision-making (OPTION-5): how it is measured was reworded
    • DescriptionProportion with adequate SDM-Q-9 score: how it is measured was reworded
    + 2 other changes: verification date and description
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858084
Responsible party
Ilana Sebbag (Clinical Associate Professor, University of British Columbia) — Principal investigator
First posted
Oct 5, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Ilana Sebbag, MD
Contact
ilana.sebbag@cw.bc.ca
604-875-2185

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion